MedTrace Logo

Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures

NCT04558580 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2020-09-22

No results posted yet for this study

Summary

This study will evaluate the efficacy and safety of Rufinamide in reducing seizure frequency in subjects with partial seizures not fully controlled despite treatment with 1 to 3 concomitant antiepileptic drugs.

Conditions

  • Refractory Partial Seizures

Interventions

DRUG

Rufinamide

Rufinamide

Sponsors & Collaborators

  • University of South Alabama

    lead OTHER

Principal Investigators

  • Paul Maertens, MD · University of South Alabama

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04558580 on ClinicalTrials.gov